Acid secretion inhibitor and use thereof
The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.
1 . A method of treating gastrointestinal ulcers, gastrointestinal inflammatory diseases, or gastric acid-related diseases, the method comprising administering to a subject in need a therapeutically effective amount of a compound represented by the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof:
in the Chemical Formula 2,
X 1 is F;
X 2 is hydrogen or F;
R 1 is methyl; and
R 2 is methoxy, ethoxy, methyl or ethyl.
2 . The method of claim 1 , wherein R 2 is methoxy or methyl.
3 . The method of claim 1 , wherein R 1 is methyl, and R 2 is methoxy or methyl.
4 . The method of claim 1 , wherein
X 1 is F;
X 2 is F;
R 1 is methyl; and
R 2 is methoxy or methyl.
5 . The method of claim 1 , wherein
X 1 is F;
X 2 is hydrogen;
R 1 is methyl; and
R 2 is methoxy or methyl.
6 . The method of claim 1 , wherein
X 1 is F;
X 2 is hydrogen or F;
R 1 is methyl; and
R 2 is methoxy.
7 . The method of claim 1 , wherein
X 1 is F;
X 2 is hydrogen or F;
R 1 is methyl; and
R 2 is methyl.
8 . The method of claim 1 , wherein the compound represented by Chemical Formula 2 is any one selected from the group consisting of the following compounds:
1-(5-(2-fluorophenyl)-4-methoxy-1-((6-methoxypyridin-3-yl) sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;
1-(5-(2,4-difluorophenyl)-4-methoxy-1-((6-methoxypyridin-3-yl) sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine;
1-(5-(2,4-difluorophenyl)-4-methoxy-1-((6-methylpyridin-3-yl) sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; and
1-(5-(2-fluorophenyl)-4-methoxy-1-((6-methylpyridin-3-yl) sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine.
9 . The method of claim 1 , wherein the gastrointestinal ulcer, gastrointestinal inflammatory disease or gastric acid-related disease is any one or more selected from the group consisting of peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, acute stress ulcer, Zollinger-Ellison syndrome, Helicobacter pylori infection, gastritis, erosive esophagitis, non-erosive esophagitis, reflux esophagitis, inflammatory bowel disease, symptomatic gastroesophageal reflux disease (symptomatic GERD), functional dyspepsia, gastric cancer, gastric MALT lymphoma, hyperacidity, and upper gastrointestinal hemorrhage due to invasive stress.
10 . The method of claim 1 , wherein the administering is oral administrating.
11 . The method of claim 1 , wherein a daily dosage of the compound is from about 0.001 to about 100 mg/kg.
12 . The method of claim 1 , wherein the compound inhibits the proton pump.
13 . The method of claim 1 , wherein the compound inhibits gastric acid secretion.